Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
Frequently asked questions
What sector does Mezzion Pharma Co.Ltd (140410) operate in?
Mezzion Pharma Co.Ltd belongs to the Healthcare sector and operates in the Pharmaceuticals industry.
What is Mezzion Pharma Co.Ltd (140410) current stock price?
As of the latest data, Mezzion Pharma Co.Ltd stock price is ₩67,800, with a previous close of ₩67,800.
What is Mezzion Pharma Co.Ltd (140410) current market capitalization?
Mezzion Pharma Co.Ltd market cap is approximately 579.44 billion.
Does Mezzion Pharma Co.Ltd (140410) pay dividends?
No. Mezzion Pharma Co.Ltd does not pay a dividend.
What is Mezzion Pharma Co.Ltd (140410) beta (volatility) score?
Mezzion Pharma Co.Ltd has a beta of 0.760, indicating lower volatility than the overall market.
